Vanguard Fiduciary Trust
MCRB icon

Vanguard Fiduciary Trust’s Seres Therapeutics MCRB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$384K Buy
48,685
+9,042
+23% +$68.8K ﹤0.01% 3359
2026
Q1 		$352K Buy
+39,643
New +$464K ﹤0.01% 3330

Other funds holding MCRB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Fiduciary Trust's MCRB Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Seres Therapeutics (MCRB) stake by 23% in Q2 2026, buying an estimated $68.8K and bringing the position to 48,685 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #3359.

Vanguard Fiduciary Trust first reported a position in MCRB in Q1 2026 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Vanguard Fiduciary Trust held 48,685 shares of Seres Therapeutics worth $384K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 9,042 Seres Therapeutics shares in Q2 2026, an estimated $68.8K.
  • Seres Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3359 holding.
  • Vanguard Fiduciary Trust first reported a position in Seres Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.